3 ASX Growth Stocks With High Insider Ownership Worth A Closer Look

With oil markets swinging on Strait of Hormuz risks and shipping costs in focus, many investors are watching inflation and interest rate paths closely. That backdrop keeps attention on companies that can grow even as borrowing stays expensive. Fast growing stocks with high insider ownership can align management with shareholders and offer potential resilience. This article highlights three standouts from that screener and explains why they deserve a closer look.

The stocks covered below are just a small sample, and the full screen surfaced 99 more companies with similarly compelling growth stories and insider alignment that are not discussed here. To identify and analyze the highest conviction ideas that best fit your portfolio, head straight to the Fast Growing Stocks With High Insider Ownership screener.

Predictive Discovery (ASX:PDI)

Overview: Predictive Discovery is a West Africa focused gold company that already has two operating mines and is working to bring its flagship Bankan Gold project in Guinea into production. The company aims to build a larger, long life gold business across Guinea, Mali and Côte d'Ivoire from its 356 square kilometre Bankan footprint and broader regional portfolio.

Market Cap: A$3.6 billion

Predictive Discovery is drawing attention because it is moving from pure explorer to a multi mine gold producer, with Kiniero and Nampala already pouring gold and the Bankan project being advanced using free cash flow rather than relying only on fresh equity. At the same time, analysts are building in very ambitious revenue and earnings forecasts and see material upside to today’s share price, even while the P/B multiple sits well above sector averages. That growth story comes with real pressure points, including a short cash runway, higher risk borrowing, recent shareholder dilution and reliance on permits in Guinea and operations in Mali. For investors, the key question is whether the growing production base and resource inventory justify accepting those risks.

Predictive Discovery is shifting from an explorer story stock to a multi-mine producer, yet the market may not be pricing that transition clearly. Before you decide what is priced in, read the 2 key rewards and 4 important warning signs (2 are major!)

Build your own high growth and insider backed shortlist

Predictive Discovery and the other two stocks in this article all came from a single screener, but the real edge comes when you shape the filters yourself. Use our customisable Screener to combine growth, valuation, balance sheet and risk metrics for your own watchlist, or tap into our curated Investing Ideas for ready made starting points.

Mesoblast (ASX:MSB)

Overview: Mesoblast is a Melbourne based biotech that develops regenerative cell therapies using mesenchymal lineage cells to treat severe inflammatory, cardiovascular and chronic pain conditions, including pediatric and adult graft versus host disease, chronic low back pain and chronic heart failure. Its lead product Ryoncil is already approved for steroid refractory acute graft versus host disease in children. Partner programs and late stage trials target larger patient populations in gut disease, heart disease and pain.

Operations: Mesoblast currently generates about US$65 million from the development and commercialization of its cell technology platform.

Market Cap: A$2.9 billion

Mesoblast catches attention because it already has Ryoncil on the market in the US with broad reimbursement and reported product gross margins around 90%, yet the company is still loss making and funding expansion with higher risk borrowing and new facilities. Investors get exposure to a broad late stage pipeline, including rexlemestrocel L in chronic low back pain and heart failure with FDA RMAT designations that could shorten review timelines. This also concentrates risk around clinical and regulatory outcomes over the next few years. Analysts see this as a story where the key issue is how much you trust Mesoblast’s execution and whether today’s valuation fairly reflects both the potential upside and the funding and trial risks still on the table.

Mesoblast’s late stage pipeline and high margin Ryoncil sales tell only part of the story. The real question is how the current valuation compares with execution risk and funding needs in the analysis report for Mesoblast.

Telix Pharmaceuticals (ASX:TLX)

Overview: Telix Pharmaceuticals develops and sells radiopharmaceutical products that help doctors image and treat cancers more precisely, with a focus on urologic cancers, brain tumours and other solid tumours across multiple global markets.

Operations: Telix Pharmaceuticals generates most of its revenue from Precision Medicine at about US$622 million, with Manufacturing Solutions contributing roughly US$245 million and Therapeutics about US$9 million, before US$73 million of inter segment eliminations.

Market Cap: A$5.1 billion

Telix Pharmaceuticals stands out because it already has meaningful revenue from cancer imaging agents like Illuccix and Gozellix, while running several Phase 3 trials that could add new treatment revenue streams if results and approvals go its way. The company is building its own manufacturing footprint, including a new radiopharmaceutical facility in Melbourne, and has attracted partners such as Regeneron, which recently paid US$40 million to co develop next generation therapies. At the same time, Telix is still loss making, relies on external borrowing and carries trial, regulatory and pricing risks that investors cannot ignore.

Telix Pharmaceuticals is scaling meaningful imaging revenue while late stage trials and new partnerships could reshape the story. To see how analysts expect that growth path to play out, review the analyst forecasts for Telix Pharmaceuticals

Seeking Alternatives Before The Crowd Moves

Fresh ideas move fast. Breakout momentum often fades once everyone is watching and the best entry points get caught in flying prices or dropping quality. Scan under the radar for now and act now.

• Spot income workhorses that could keep portfolios funded through thick and thin by reviewing the 4 dividend fortresses before others chase the yields.
• Ride the potential data center and chip momentum by checking the curated 56 AI infrastructure stocks while these enablers of AI demand are still early in wider attention.
• Position ahead of possible electrification tailwinds by scanning the focused 8 top copper producer stocks so you are not scrambling after the next commodity story heats up.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com